Use of propensity score in cost-effectiveness analysis using drug-eluting and bare metal stents  by Ferreira, Esmeralci et al.
Use of Propensity Score in Cost-Effectiveness  
Analysis of Drug-Eluting and Bare-Metal Stents
Esmeralci Ferreira1-5, Denizar Vianna Araújo1, Vitor Manuel Pereira Azevedo2, Alcides Ferreira Jr.3,4,  
Camillo de Lellis Carneiro Junqueira1,4, Bernardo Amorim3, Edgar Freitas Quintella1,3,  
Cyro Vargues Rodrigues3,4, Antonio Farias Neto5, Denilson Campos de Albuquerque1
Rev Bras Cardiol Invasiva. 
2012;20(1):21-8
ABSTRACT
Background: Studies on the cost-effectiveness ratio of drug-
eluting stents (DES) are rare. This study aimed to evaluate 
the results and compare the cost (incremental cost-effec-
tiveness ratio – ICER) per restenosis prevented between DES 
and bare-metal stents (BMS) using the propensity score. 
Methods: Two hundred and twenty consecutive patients were 
included in the study, 111 of whom were treated with DES 
and 109 with BMS. The propensity score was used to adjust 
the effect of the intervention by means of matching, stratifica-
tion and weighting. Results: Most patients were male (67.7% 
vs. 66.9%; P  =  0.53), with a median age of 65.9 years. 
Patients treated with DES had higher rates of diabetes (54% 
vs. 17.4%; P < 0.001), three-vessel disease (18.9% vs. 10.1%; 
P  =  0.029) and poor ventricular function (54.1% vs. 22%; 
P < 0.0001). The diameter of stents was 2.76 ± 0.35 mm vs. 
2.91 ± 0.47 mm (P = 0.006), and the sum of the lengths of 
stents was 37.6 ± 23 mm vs. 24.8 ± 15.8 mm (P < 0.0001). 
Restenosis was observed in 6.3% vs. 12.8% of the patients 
(P = 0.099) and in 4.1% vs. 9.8% of the lesions (P = 0.048). 
There was an incremental cost of R$ 9,500.00 and an ICER 
of R$  147,538.00 per restenosis prevented (exceeding the 
World Health Organization threshold). However, when the 
propensity score was used, the variables that best classified 
patients for DES and had a maximum ICER of R$  4,776.96 
were age >  72 years, diabetes and lesions <  3.2  mm in 
diameter and >  18  mm in length. Conclusions: Although 
DES were not cost-effective in the total population, the 
propensity score showed that in elderly patients, diabetics, 
and patients with long lesions or small vessels, the use of 
DES was cost-effective.
DESCRIPTORS: Coronary disease. Drug-eluting stents. Cost-benefit 
analysis.
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RESUMO
Uso do Escore de Propensão na Análise de  
Custo-Efetividade com Utilização Seletiva de  
Stents Farmacológicos e Não Farmacológicos
Introdução: Os estudos sobre a razão de custo-efetividade dos 
stents farmacológicos (SFs) são escassos. Nosso objetivo foi ava-
liar os resultados e comparar os custos (razão custo-efetividade 
incremental – RCEI) por reestenose evitada entre SFs e stents 
não farmacológicos (SNFs) utilizando o escore de propensão. 
Métodos: Incluímos na análise 220 pacientes tratados conse-
cutivamente, dos quais 111 com SFs e 109 com SNFs. O escore 
de propensão foi usado para ajustar o efeito da intervenção por 
meio de pareamento, estratificação e ponderação. Resultados: 
Predominaram pacientes do sexo masculino (67,7% vs. 66,9%; 
P = 0,53), com média de idade de 65,9 anos. Pacientes trata-
dos com SFs apresentaram maior frequência de diabetes (54% 
vs. 17,4%; P < 0,001) e doença triarterial (18,9% vs. 10,1%; 
P = 0,029) e pior função ventri cu lar (54,1% vs. 22%; P < 0,0001). 
O diâmetro dos stents foi de 2,76 ± 0,35 mm vs. 2,91 ± 0,47 mm 
(P = 0,006) e a soma do comprimento dos stents foi de 
37,6 ± 23 mm vs. 24,8 ± 15,8 mm (P < 0,0001). Reestenose 
ocorreu em 6,3% vs. 12,8% dos pacientes (P = 0,099) e em 
4,1% vs. 9,8% das lesões (P = 0,048). Houve incremento de 
custo de R$ 9.590,00 e a RCEI foi de R$ 147.538,00 por rees-
tenose evitada (acima do limiar da Organização Mundial da 
Saúde). Entretanto, utilizando o escore de propensão, as variáveis 
que melhor classificaram os pacientes para SFs e apresentam 
RCEI máxima de R$ 4.776,96 foram idade > 72 anos, diabetes 
e lesões com diâmetro < 3,2 mm e comprimento > 18 mm. 
Conclusões: Apesar de os SFs não terem sido custo-efetivos na 
população em geral, o escore de propensão demonstrou que 
em idosos, diabéticos e pacientes com lesões longas ou vasos 
de fino calibre o uso de SFs foi custo-efetivo.
DESCRITORES: Doença das coronárias. Stents farmacológicos. 
Análise custo-benefício.
Brazilian national clinical practice shows that although the use of drug-eluting stents (DES) significantly contributes to the treatment of coronary artery 
disease, it is still exclusive to wealthy patients or to 
those who have prepaid health plans.1 In Brazil, few 
studies have mentioned the implications of the cost-
effectiveness of DES.2–5 Although the use of DES has not 
been cost-effective in the populations evaluated, none 
of these studies has shown the real financial impact of 
its use, as they were non-randomised studies.
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Despite the natural selection bias when more complex 
patients are treated with DES the results are higher than 
those found with bare-metal stents (BMS). Propensity score 
matching enables the correction or at least minimisation 
of the selection bias between DES and BMS. 
The propensity score is defined as the probability 
of exposure to a treatment, according to each variable 
used in the matching. The score is usually obtained from 
logistic regression and varies from 0 to 1, reflecting 
each individual’s probability (based on their character-
istics) of receiving the treatment of interest. Therefore, 
individuals with the same score have equal chances of 
receiving treatment even though they may not present 
the same characteristics, A ‘virtual randomisation’, in 
which comparable patients may be separated between 
exposed and non-exposed patients, may be obtained 
by analysing similar propensity scores. 
This study aimed to compare the clinical results 
and the medium-term incremental cost-effectiveness ratio 
(ICER) between patients with DES and those with BMS. 
Due to the impossibility of randomisation, a propensity 
score was used to calculate the ICER in order to adjust 
the intervention effect by means of matching, stratifica-
tion, and weighting between the groups, and thus classify 
the patients who most benefited from the use of DES.
METHODS
A prospective cohort, consecutive, non-randomised 
study was conducted with 220 patients undergoing per-
cutaneous coronary intervention (PCI) with implantation 
of one or more stents in private healthcare institutions 
in Rio de Janeiro, Brazil. The patients were divided 
into two groups: one group of 111 patients treated 
with DES, who used one or more Taxus® stents (Boston 
Scientific – Natick, MA, USA), and another group of 
109 patients treated with BMS, who used one or more 
Liberté® stents (Boston Scientific – Natick, MA, USA). 
Patients with stable angina or acute coronary syn-
drome without ST-segment elevation were included. 
Patients with acute myocardial infarction and cardiogenic 
shock were excluded. Procedures were conducted by 
six professionals from three institutions. BMS implants 
were mostly suggested for less complex lesions, when 
the long-term use of thienopyridines was not possible 
or due to financial issues limiting the use of DES.
While the patients were in hospital, success, death, 
myocardial infarction, target lesion revascularisation, 
stent thrombosis and direct costs were evaluated. 
The follow-up with all patients was conducted either 
via telephone or via appointments with a physician. 
Clinical restenosis occurred when symptom recurrence 
was observed. Only patients who developed restenosis 
underwent cardiac catheterisation. The dual antiplatelet 
therapy was maintained for three months following BMS, 
and for at least one year following DES. 
Statistical analysis
The chi-squared test or Fisher’s exact test were used, 
and the 95% confidence interval (CI) and the mean ± 
standard deviation of all variables were calculated. In 
the survival analysis and in the event-free survival, the 
Kaplan-Meier method and the log rank test were used. 
The Cox method was used in the multivariate analysis. 
STATISTICA 8 (StatSoft Inc., Houston, TX, USA) was used 
in the analysis. The results were considered statistically 
significant when P  <  0.05. 
Cost analysis
A decision-analytic model was developed to estimate 
the probabilities of outcomes and costs of DES vs. BMS. 
These models are developed through the chronological 
sequence of problem identification, problem structuring 
(decision tree) and parameterisation of model analysis 
(cost estimates, outcomes and risks).6 Effectiveness data 
were obtained from the study cohort. The costs due to 
intervention were calculated as direct costs: hospital 
stays, complementary examinations, stent prices, medi-
cation and professional fees. Costs were calculated in 
Brazilian reals, based on the currency value in 2005. 
The currency exchange rate was established on Decem-
ber 31, 2005 (US$ 1.00 = R$ 2.34). The prices of the 
medications were calculated based on the Brasíndice 
table on June 30, 2005 (maximum consumer price 
[preço máximo ao consumidor – PMC]).7 The price of 
the complementary examinations was obtained from 
the Brazilian Hierarchical Classification of Medical 
Procedures (Classificação Brasileira de Hierarquização 
de Procedimentos Médicos – CBHPM, 2003).8 Con-
cerning the stents, the price of the purchases by the 
participant institutions was considered, and the unit 
price for each device was R$ 4,200.00 for the BMS 
and R$ 11,762.00 for the DES. 
The ICER9 was calculated by dividing the differ-
ence of direct costs between the DES and BMS by the 
effectiveness difference (one-year event-free survival 
for restenosis). Figure 1 shows the formula used for 
calculating the ICER between the implants with DES 
vs. BMS. The incremental cost suggested by the World 
Health Organization (WHO) is up to three times the 
gross domestic product (GDP) per capita per year of life 
saved. In this period, for the calculus base suggested 
by the Brazilian Institute of Geography and Statistics 
(Instituto Brasileiro de Geografia e Estatística – IBGE, 
the total amount was US$  20,313.00.10 The statistical 
analysis of the decision model was obtained by the 
TreeAge Pro Healthcare Module, version 2005 (TreeAge 
Software Inc. – Williamstown, MA, USA).
Propensity score
The matching procedure with balanced scores 
was used, and the score was calculated based on 
a logistic regression model that varied from 0 to 1, 
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describing the probability of each individual receiving 
the necessary treatment according to their characteris-
tics. Logarithmic odds were specifically used. A logit 
model was estimated by using all predictor variables 
in order to obtain the probability and calculate the 
logarithmic odds ratio for each observation in the 
sample of each individual group.11,12 
The propensity score was developed to predict 
with maximum distinction the probability that a pa-
tient would receive a BMS, and it was considered an 
overfitted logistic model. In addition, by optimising 
the variance in the entrance of each clinical feature, 
it was guaranteed that for each probability produced 
by the model there would be representatives of both 
stent types. Finally, six strata with probability zones 
were generated to guarantee the described purpose. 
The ICER was analysed after the calculation of the 
propensity score to estimate the subgroups classified 
to receive the DES.
Ethical aspects
The study protocol was approved by the Research 
Ethics Committee of the Universidade do Estado do 
Rio de Janeiro (PROJECT 681 A) and was established 
according to the present scientific guidelines.13
RESULTS
Most patients were male (67.7% vs. 66.9%; 
P = 0.53), with a median age of 65.9 years (42 to 91 
years). Patients treated with DES had higher rates of 
diabetes (54% vs. 17.4%; P < 0.001), prior myocardial 
infarction (48.6% vs. 28.4%; P  =  0.002) and prior re-
vascularisation procedures than the BMS group (21.7% 
vs. 5.5%; P  =  0.005) (Table 1).
Concerning the angiographic features, patients 
treated with DES presented a higher rate of three-vessel 
disease (18.9% vs. 10.1%; P  =  0.029) and poor ven-
tricular function (54.1% vs. 22%; P  <  0.0001). There 
was no difference regarding the number of lesions 
treated per patient (1.51 vs. 1.31; P  =  0.18), but the 
group treated with DES showed a higher incidence of 
type B2 complex lesions (30.4% vs. 18.1%; P = 0.01). 
The most treated artery was the left anterior descending 
artery (35.6% vs. 37.6%; P  =  0.69). Mammary grafts 
(4.3% vs. 0.7%; P = 0.052) and lesions of the left main 
coronary artery (3.6% vs. 0; P = 0.02) were frequently 
treated with DES (Table 2). 
Concerning the procedure, the diameter of DES 
vs. BMS was 2.76  ±  0.35  mm vs. 2.91  ±  0.47  mm 
(P  =  0.006), and the sum of the lengths of stents was 
37.6 ± 23 mm vs. 24.8 ± 15.8 mm (P < 0.0001). The 
average hospital stay was similar in both groups (1.75 
days vs. 1.49 days; P  =  0.21).
In the late follow-up (average of 17 months), the 
frequency of asymptomatic patients was 85.6% vs. 
79.8% (P  =  0.25) in the DES and BMS groups, re-
spectively. The number of cardiac (4 vs. 6; P = 0.50) 
and non-cardiac deaths (1 vs. 1; P = 0.96) was similar 
between the groups (Table 3). Among the four cardiac 
deaths within the group treated with DES, one was 
due to restenosis with myocardial infarction treated 
with primary angioplasty, and three were due to con-
gestive heart failure. Among the six deaths of patients 
treated with BMS, one presented sudden death, and 
the others presented acute coronary syndrome without 
ST-segment elevation. 
Restenosis was observed in 6.3% vs. 12.8% of 
the patients (P  =  0.099) and in 4.1% vs. 9.8% of the 
lesions (P  =  0.048). There were 11 revascularisations 
in the DES group, seven to treat restenosis and four to 
treat de novo lesions. Among the restenoses, two were 
treated with a new PCI, four with coronary artery bypass 
graft surgery and one in a conservative manner. In the 
BMS group, there were 15 new revascularisations, 14 
to treat restenosis and one to treat de novo lesions. 
Among the 14 restenoses, seven were clinically treated, 
six through PCI and one through surgery. 
The two-year survival rates were 96.2% in the DES 
group and 89.3% in the BMS group (P  =  0.76). 
Concerning costs, the decision tree was modelled 
in the restenosis of the DES group (6.3%) vs. the BMS 
group (12.8%) over the average follow-up of 17 months. 
Figure 2 shows the decision tree with the rates and 
costs related to both groups and presents the relation-
ship between cost and effectiveness. 
 The net benefit of the DES implant was 6.3% re-
stenosis reduction, and there was an incremental cost of 
R$ 9,590.00. The ICER was R$ 147,538.00 per resteno-
sis prevented, whose incremental price was above the 
threshold suggested by the World Health Organization 
(R$ 47,532.00).10 Therefore, the DES implant proved to 
be a non-cost-effective treatment (Table 4). 
Considering restenosis (Table 5) and survival (Table 
6) separately, the analysis of the propensity score for 
ICER showed that patients who were >  72 years old, 
patients with diabetes, and patients who had lesions 
<  3.2  mm in diameter and >  18  mm in length were 
the best-qualified subgroups to receive DES. These 
 DES cost – BMS cost
ICER =
 DES effectiveness – BMS effectiveness
Figure 1 – Formula to calculate the incremental cost-effectiveness ratio 
between drug-eluting stent implantation and bare-metal stent implanta-
tion. Costs = hospital stays, complementary examinations, percutane-
ous procedure, professional fees, and stent prices (drug-eluting stents 
and bare-metal-stents); effectiveness = one-year event-free survival for 
restenosis; ICER = incremental cost-effectiveness ratio; DES = drug-
eluting stent; BMS = bare-metal stent.
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subgroups represented strata in which ICER varied 
from R$  536.33 to R$ 4,776.96, within the threshold 
suggested by the WHO.
DISCUSSION
In a real-world analysis comparing DES to BMS, 
this study has shown that the patients from the DES 
group presented more complex clinical and angio-
graphic features, but similar clinical events, compared 
with the BMS group. The incidence of clinical reste-
nosis did not show significant differences, nor did 
the survival curves. The rate of restenosis due to the 
lesion was higher in the group treated with BMS, but 
this group’s results exceeded expectations, probably 
due to the sensible selection of patients with a less 
favourable profile. Therefore, the comparison of the 
ICER of the two groups showed that DES are not cost-
effective compared to the BMS. The propensity score 
used demonstrated that the variables age > 72 years, 
diabetes and < 3.2-mm-diameter and > 18-mm-length 
lesions were the best factors to classify the groups, 
leading to a cost-effective ICER. 
Despite the fact that the propensity score is a tool 
to understand the differences between groups, this ‘ficti-
tious randomisation’ does not replace the main advantage 
of randomisation, which is to generate homogeneous 
groups in relation to unknown variables. 
Although the development of new technologies 
and devices related to intervention helps to reduce 
costs, the financial burden necessary to implant these 
devices is still very high, and this remains the physi-
cian’s major challenge. 
The different results between the groups are the 
consequence of a better late evolution in patients 
receiving DES. The limited use of DES, whether in 
Brazil or in developed countries, is exclusively related 
to costs,1–5 which are still very high. The perspective of 
better results in more severe patients compared with 
patients in less severe conditions is the largest factor 
contributing to the use of DES.14,15 Therefore, this article 
aimed to investigate the societal cost of the use of DES 
in a complex clinical scenario. 
The WHO suggests that the incremental cost of the 
treatment present a threshold equivalent to three times 
the per capita GDP. According to IBGE, in 2005 the 
per capita GDP was US$  6,771.00, which generates 
a threshold of US$  20,313.00 (R$  47,532.00) for the 
treatment’s incremental cost.10 
In this clinical case, the incremental cost of R$ 9,590.00 
(US$  4,098.00) for each DES corresponds to a cost-
effectiveness of R$  18,452.00 (US$  7,885.00) per reste-
nosis prevented. The cost-effectiveness of R$  8,830.00 
(US$  3,773.00) per restenosis prevented by using DES 
corresponds to an ICER of R$ 147,538.00 (US$ 63,050.00), 
TABLE 1 
Clinical Features and Comorbidities in the Study Population
Variable
Drug-eluting Stent 
(n = 111) 
Bare-metal Stent 
 (n = 109) P 
Median age, years 67.1 (42-91) 65.4 (43-90) 0.33
Male gender, n (%) 74 (67.7) 73 (66.9) 0.53
Diabetes mellitus, n (%) 60 (54) 19 (17.4) < 0.001
Hypertension, n (%) 83 (74.7) 89 (81.6) 0.22
Dyslipidaemia, n (%) 63 (56.7) 55 (50.4) 0.35
Tobacco smoking, n (%) 13 (11.7) 20 (18.3) 0.17
Obesity, n (%) 28 (25.2) 27 (24.7) 0.94
Sedentary lifestyle, n (%) 53 (47.7) 43 (39.4) 0.21
Family history of CAD, n (%) 43 (38.7) 24 (22.1) 0.007
Prior myocardial infarction, n (%) 54 (48.6) 31 (28.4) 0.002
Prior revascularisation, n (%) 24 (21.7) 6 (5.5) 0.005
Clinical picture, n (%) 
Stable angina 63 (56.7) 74 (68) 0.40
Unstable angina 48 (43.3) 35 (32) 0.088
CAD = coronary artery disease; n = number of patients. 
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which is above the acceptable threshold of R$ 47,532.00. 
Therefore, the DES implant proved to be a non-cost-
effective treatment strategy. 
The decision tree of the cost-effectiveness analysis 
shows that the DES provided a net benefit of 6.3% re-
stenosis reduction. Nevertheless, the cost increment per 
stent, cost per restenosis prevented, as well as the ICER 
factors,confirm the hypothesis that DES are not cost-effective 
when compared with BMS in private health systems. 
Besides the additional cost of DES, the low rates 
of restenosis and of new interventions among patients 
treated with BMS contributed to cost reduction in these 
TABLE 2 
Angiographic Profile and Ventricular Function of the Study Population
Angiographic  
Features 
Drug-eluting Stent 
(n = 111) 
Bare-metal Stent 
 (n = 109) P 
Ventricular function < 0.0001
Normal/discrete 51 (45.9) 85 (78)
Moderate/severe 60 (54.1) 24 (22)
Types of Lesion 
A 43 (25.6) 65 (45.5) 0.0002
B1 50 (29.7) 35 (24.5) 0.30
B2 51 (30.4) 26 (18.1) 0.01
C 24 (14.3) 17 (11.9) 0.53
Treated arteries 
LMC 6 (3.6) 0 (0) 0.02
LAD 58 (35.6) 53 (37.6) 0.69
Diagonal branch 8 (4.8) 10 (7.1) 0.36
LCx 34 (20.7) 23 (16.3) 0.32
RCA 43 (26.2) 50 (35.5) 0.08
Saphenous vein 8 (4.8) 4 (2.8) 0.36
Mammary artery 7 (4.3) 1 (0.7) 0.052
RCA = right coronary artery; LCx = left circumflex artery; LAD= left anterior descending artery; n = number of patients; LMC= left main 
coronary artery.
TABLE 3 
Follow-up of the Study Population
Evolution
Drug-eluting stent
 (n = 111)
Bare-metal stent
 (n = 109) P
Event-free 95 (85.6) 87 (79.8) 0.25
Cardiac death 4 (3.6) 6 (5.5) 0.50
Non-cardiac death 1 (0.9) 1 (0.9) 0.96
Angina pectoris 11 (9.9) 15 (13.8) 0.38
Angiographic restenosis 7 (6.3) 14 (12.8) 0.099
De novo lesion 4 (3.6) 1 (0.9) 0.181
Restenosis lesion 7 (4.1) 14 (9.8) 0.048
n = number of patients. 
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patients. This positive response may be explained by the 
good performance of BMS and by the selective indica-
tion of patients. Consequently, differences in costs are 
important factors in the non-cost-effectiveness of DES 
compared with BMS.
The treatment of an extremely heterogeneous 
population, in which the events in the BMS group were 
below expectations, provides the best explanation for 
the failure to achieve an ICER that favoured the use of 
DES. Additionally, the results were influenced by the fact 
that a control angiographic protocol was not elaborated. 
The decision model in which the economic calcula-
tions were based is strongly effectiveness-dependent 
and considers restenosis rates of 30% in patients with 
BMS and 6% in patients with DES.
Previous studies have shown unequal results concern-
ing the analysed population and the DES cost. In Brazil, 
the model developed to compare sirolimus-eluting stents 
with standard stents in patients with the same type of 
lesion has shown that the costs of sirolimus stents are 
partially compensated within the first year, especially 
in high-risk subgroups. However, the additional costs 
considered acceptable for certain clinical intervention 
benefits have not been established in Brazil.2-5
In the real world, DES are less cost-effective than 
in controlled studies. These stents must be used par-
ticularly in high-risk patients. Randomised studies16-21 
have shown that the use of DES was cost-effective. In 
the Basel Stent Kosten-Effektivitäts Trial (BASKET), Kaiser 
et al.22 included 826 patients and demonstrated that 
the high cost of DES was not compensated by cost 
reduction during the follow-up. However, DES were 
cost-effective in the elderly and in high-risk patients. 
The cost outcomes demonstrated in randomised 
studies do not reflect the experience and records of 
the real world, especially due to different rates of new 
revascularisations between the two study methodologies. 
In the Rapamycin-Eluting Stent Evaluated At Rot-
terdam Cardiology Hospital (RESEARCH) study, Lemos 
et al.23 evaluated the use of BMS (450 patients) vs. the 
use of DES (508 patients) in a real world setting. In a 
one-year period, the event rate was 14.8% in patients 
with BMS and 9.7% in patients with DES, revealing 
that the use of DES was not cost-effective. Ferreira 
et al.24 followed-up 217 patients with single-vessel 
coronary artery disease treated with only one stent, 
and observed an ICER of R$ 131,647.84 per restenosis 
that was prevented. The present study's findings are in 
agreement with the ICERs found by Lemos et al.23 and 
by Ferreira et al.,24 which confirms that non-randomised 
studies are not cost-effective.
Cost-effective estimates are sensitive to several vari-
ables. It is still a challenge to establish the real impact 
of DES in clinical practice. Regional factors, market price 
and the number of stents per patient may also influence 
cost-effectiveness. The decision to limit the use of DES to 
high-risk patients who are likely to develop restenosis can 
improve its cost-effectiveness, but it will be necessary to 
find evidence to compare the absolute benefits among the 
patient groups. This study was relevant since, by means 
of the propensity score, the benefits of DES use resulting 
from its cost-effectiveness in certain subgroups of a cohort 
were clearly shown for the first time. The follow-up of 
all patients and the use of propensity score demonstrated 
that the use of DES in specific subgroups is cost-effective 
in spite of the impossibility of randomisation.
TABLE 4 
Incremental Cost-effectiveness Ratio between Drug-eluting Stent  
Implantation and Bare-metal Stent Implantation
Drug-eluting stent Bare-metal stent 
Cost R$ 17,290.00 R$ 7,700.00
Incremental cost R$ 9,590.00
Effectiveness 0.937 0.872
Incremental effectiveness 0.065
Cost-effectiveness R$ 18,452.00* R$ 8,830.00*
ICER R$ 147,538.00
* Per restenosis that was prevented. 
ICER = incremental cost-effectiveness ratio.
Figure 2 – Decision tree of cost effectiveness between drug-eluting stents 
and bare-metal stents. DES = drug-eluting stent; PCI = percutaneous 
coronary intervention; BMS = bare-metal stent.
PCI
0.063
R$ 17,290.00/0.937
R$ 17,290.00/0.937
R$ 7,700.00/0.872
R$ 7,700.00/0.872
0.937
0.128
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BMS
Restenosis
Restenosis
Without restenosis
Without restenosis
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Limitations of the study
As this study used records provided by private 
institutions, it was not possible to perform an appropri-
ate randomisation with a control group. Because the 
physicians decided the follow-up of the patients, total 
angiographic control was not possible, especially in the 
asymptomatic patients in this study. Therefore, it is not 
possible to say that no patient died of clinically silent 
restenosis. The number of patients from this population 
was limited, but it allowed for inference of the evolution 
of these patients during the study period.
CONCLUSIONS
This study demonstrated that, in national clinical 
practice, patients treated with DES presented a more 
complex clinical and angiographic profile than those 
treated with BMS, but both presented similar clinical 
events. Although the rates of restenosis due to lesions 
were higher in the group treated with BMS, the ICER 
showed that DES are not cost-effective in the total 
population. The use of propensity score to reduce the 
differences between the groups showed that DES are 
cost-effective in the subgroups of the elderly, diabetics 
and patients with long lesions or small vessels.
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TABLE 5 
Propensity Score for Incremental Cost-effectiveness Ratio and One-year Restenosis
Stratum
BMS  
(n)
DES 
(n)
Age 
> 72 years
(%)
Diabetes
(%)
Diameter 
< 3.2 mm 
(%)
Length 
> 18 mm 
(%)
Restenosis  
(%) 
ICER
(R$)
1 27 7 7.4 2.3 6 0.5 30 1,526.40
2 35 32 28.6 2.3 25.3 5.5 60.8 1,091.86
3 6 10 0 0 7.4 7.4 14.7 2,167.19
4 4 24 12.9 12.9 11.5 1.4 24.9 Equiv. effic.
5 12 35 5.1 5.1 21.7 21.7 41.9 536.33
6 3 22 11.5 11.5 11.5 11.5 21.7 4,776.96
ICER = incremental cost-effectiveness ratio; DES = drug-eluting stent; BMS = bare-metal stent; R$ = Brazilian reals. 
TABLE 6 
Propensity Score for Incremental Cost-effectiveness Ratio and One-year Survival 
Stratum
BMS  
(n)
DES 
(n)
Age 
> 72 years
(%)
Diabetes
(%)
Diameter 
< 3.2 mm 
(%)
Length 
> 18 mm 
(%)
Restenosis  
(%) 
ICER
(R$)
1 27 7 7.4 2.3 6 0.5 30 7,143.04
2 35 32 28.6 2.3 25.3 5.5 60.8 5,132.89
3 6 10 0 0 7.4 7.4 14.7 10,550.37
4 4 24 12.9 12.9 11.5 1.4 24.9 Equiv. effic.
5 12 35 5.1 5.1 21.7 21.7 41.9 2,402.46
6 3 22 11.5 11.5 11.5 11.5 21.7 22,263.37
ICER = incremental cost-effectiveness ratio; DES = drug-eluting stent; BMS = bare-metal stent; R$ = Brazilian reals.
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